Form 4: Renovaro Biosciences Director Acquires Options to Purchase 48,137 Shares
SEC Form 4
Gregg H. Alton, a director of Renovaro Biosciences Inc., acquired options to purchase 48,137 shares of common stock on June 25, 2024.
Summary
- On June 25, 2024, Gregg H. Alton, a director of Renovaro Biosciences Inc., acquired options to purchase 48,137 shares of the company's common stock.
- The exercise price of these options is $1.61 per share.
- The options are exercisable immediately and expire on June 25, 2034.
- Following this transaction, Alton directly owns options to purchase 48,137 shares of Renovaro Biosciences Inc.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of an insider transaction. The acquisition of options could be seen as a positive signal, but it's not definitive.
Positives
- A director's acquisition of options may signal confidence in the company's future prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. These filings provide transparency to the market regarding insider activity.
Stakeholder Impact
- Shareholders may view the director's option acquisition as a positive sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 06/25/2024 | Date of transaction: Gregg H. Alton acquired options to purchase shares. |
| 06/25/2024 | Date options exercisable: Options become immediately exercisable. |
| 06/25/2034 | Expiration date of the options. |
| 06/27/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.